Company Filing History:
Years Active: 2018-2023
Title: George Thom: Innovator in Antibody Research
Introduction
George Thom is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 3 patents, his work focuses on addressing critical health issues related to the central nervous system.
Latest Patents
One of George Thom's latest patents is centered around antibodies to alpha-synuclein and their uses. This invention provides antibodies that specifically bind to human α-synuclein with high affinity, effectively reducing α-synuclein spreading in vivo. The patent also includes recombinant polypeptides that comprise these antibodies or their antigen-binding fragments. Furthermore, it outlines methods for generating such polypeptides, as well as compositions and techniques for producing α-synuclein antibodies. The ultimate goal of this research is to utilize α-synuclein antibodies for the treatment of diseases of the central nervous system, particularly alpha-synucleinopathies.
Career Highlights
George Thom is currently associated with Medimmune Limited, where he continues to advance his research in antibody development. His innovative work has positioned him as a key figure in the biotechnology sector, contributing to the understanding and treatment of neurodegenerative diseases.
Collaborations
Throughout his career, George has collaborated with notable colleagues, including Darren Schofield and Michael Perkinton. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.
Conclusion
George Thom's contributions to antibody research are paving the way for new treatments in the field of neurodegenerative diseases. His innovative patents and collaborations highlight the importance of continued research in biotechnology.